Key facts
- Huna’s last known valuation is $7.6M (Jul 2022).
- It has raised $2.4M; the latest was Seed Round ($1.5M) in May 2025.
- Notable investors include Fondation Botnar, Big Bets, Google Accelerator, Kortex Ventures, Kunumi Serviços em Tecnologia da Informação — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Huna
- ·The full record, as it builds
Funding rounds
No funding rounds for Huna are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Huna
Developer of a cancer screening technology designed to make early cancer detection faster, cheaper, and accessible for everyone. The company offers an AI-powered risk stratification model that analyzes blood biomarkers and age to analyze blood exams, supporting early cancer detection and the identification of other diseases, enabling healthcare providers to identify high-risk individuals and prioritize care, ultimately improving patient outcomes and reducing mortality rates.
- Sector
- Healthcare
- HQ
- Sao Paulo, Brazil
- Founded
- 2021
- Employees
- 37
- Website
- huna.ai/
- Ownership
- Privately Held (backing)
Huna doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Huna shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Huna in its N-PORT filings yet. We sweep new filings monthly.